SGLT2 inhibitor found to reduce endothelial dysfunction associated with ALDH2 alcohol face flushing variant

A team of researchers at Stanford University working with two colleagues from Greenstone Biosciences has found that an SGLT2 inhibitor can reduce endothelial dysfunction commonly associated with the ALDH2 alcohol facial flushing variant.

This article was originally published on

You may also be interested in:

Read More:

Lawyers Lookup